Log in
ASX:PTX

Prescient Therapeutics Limited (PTX.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.04
MA: A$0.04
A$0.04
52-Week Range N/A
Volume537,831 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9692 7222
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 million
Book ValueA$0.03 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Prescient Therapeutics Limited (PTX.AX) (ASX:PTX) Frequently Asked Questions

What stocks does MarketBeat like better than Prescient Therapeutics Limited (PTX.AX)?

Wall Street analysts have given Prescient Therapeutics Limited (PTX.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prescient Therapeutics Limited (PTX.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Prescient Therapeutics Limited (PTX.AX)'s key competitors?

What other stocks do shareholders of Prescient Therapeutics Limited (PTX.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics Limited (PTX.AX) investors own include SkyCity Entertainment Group Limited (SKC.AX) (SKC) and Finders Resources (FND).

Who are Prescient Therapeutics Limited (PTX.AX)'s key executives?

Prescient Therapeutics Limited (PTX.AX)'s management team includes the following people:
  • Mr. Yatomi-Clarke Steven Lee, MD, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, CFO & Company Sec. (Age 47, Pay $114k)
  • Prof. Said M. Sebti Ph.D., M.D., Chief Scientific Officer
  • Dr. Terrence G. Chew, Chief Medical Officer (Age 73, Pay $155.99k)
  • Dr. James D. Winkler, Head of Bus. Devel. (Age 65)

What is Prescient Therapeutics Limited (PTX.AX)'s stock symbol?

Prescient Therapeutics Limited (PTX.AX) trades on the ASX under the ticker symbol "PTX."

How big of a company is Prescient Therapeutics Limited (PTX.AX)?

Prescient Therapeutics Limited (PTX.AX) has a market capitalization of $0.00 and generates $1.08 million in revenue each year.

What is Prescient Therapeutics Limited (PTX.AX)'s official website?

The official website for Prescient Therapeutics Limited (PTX.AX) is www.ptxtherapeutics.com.

How can I contact Prescient Therapeutics Limited (PTX.AX)?

The company can be reached via phone at 61 3 9692 7222.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.